Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases.
OBJECTIVE
To study the electroclinical and histopathologic profile of idiopathic inflammatory myositis (IIM) with reference to prognosis and survival rate.


METHODS
Diagnosis of IIM was based on the Bohan and Peter criteria. Patients who improved and those whose condition worsened or who expired due to IIM per se at last follow-up were classified to have favorable and poor outcomes, respectively. Fisher's exact test was used for univariate analysis of prognostic factors.


RESULTS
The study cohort consisted of consecutive 68 patients with IIM. The mean age at diagnosis was 36.5 years and females constituted 71%. Of these patients, 62% had definite IIM, 49% had polymyositis, 20% had dermatomyositis, and 29% had overlap syndrome. The mean follow-up period was 5.4 years. Prednisolone alone was used in 55 (80%), and azathioprine (1-3 mg/kg/day) alone in 12 (17.6%) as the initial treatment. Relapse of IIM with drug withdrawal was seen in 15 patients (22%); 70% had favorable outcome and 16% had expired. The treatment delay of ≤6 months (P = 0.001), absence of cardiac or lung involvement (P < 0.001), and positive biopsy (P = 0.033) were predictive of a favorable prognosis in the univariate analysis. In multivariate analysis, only the duration of illness of ≤6 months (P = 0.008) and the absence of cardiac or lung involvement (P = 0.001) predicted the favorable outcome at last follow-up. Cumulative survival rate was 95% at 1 year, 86% at the 5th year, and 80% at the 10th year.


CONCLUSIONS
Approximately, two-thirds of the patients showed good electroclinical and histopathologic correlations and an equal number improved with treatment. The treatment delay (≥6 months), presence of cardiac or pulmonary involvements, and negative muscle biopsy are bad prognostic factors.
Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India.
K N
KN
Ramesha
Abraham
A
Kuruvilla
P S
PS
Sarma
V V
VV
Radhakrishnan
Autoimmunity. 2006 May;39(3):205-15
16769654
J Rheumatol. 2001 Oct;28(10):2230-7
11669162
Neuroepidemiology. 1987;6(3):120-9
3658081
Clin Rheumatol. 2010 Jan;29(1):45-51
19763666
Ann Rheum Dis. 1992 Jan;51(1):41-4
1540036
Arq Neuropsiquiatr. 2000 Sep;58(3B):789-99
11018813
Ann Rheum Dis. 2006 Nov;65(11):1456-61
16606652
Brain. 1975 Dec;98(4):637-66
1218371
Muscle Nerve. 1997 Jun;20(6):651-64
9149071
Can Med Assoc J. 1985 Mar 15;132(6):649-53
3872156
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003643
16034905
J Assoc Physicians India. 2002 Oct;50:1255-8
12568209
J Rheumatol. 1985 Dec;12(6):1140-8
4093921
Semin Arthritis Rheum. 1996 Aug;26(1):447-58
8870112
Ann N Y Acad Sci. 2005 Jun;1051:64-71
16126945
J Med Invest. 2007 Aug;54(3-4):295-302
17878679
Ann Rheum Dis. 1993 Dec;52(12):857-61
8311535
Neurology. 2008 Feb 5;70(6):418-24
17881720
Neurology. 2003 Aug 12;61(3):316-21
12913190
J Neurol Neurosurg Psychiatry. 2003 Jun;74 Suppl 2:ii25-ii31
12754326
Medicine (Baltimore). 2004 Jan;83(1):35-42
14747766
Neurol India. 2008 Jul-Sep;56(3):356-62
18974564
Clin Rheumatol. 2006 Mar;25(2):234-9
16477398
Rheumatology (Oxford). 2002 Jan;41(1):22-6
11792875
J Clin Rheumatol. 2005 Jun;11(3):153-6
16357735
Clin Exp Rheumatol. 2000 Mar-Apr;18(2):241-4
10812498
Rev Rhum Engl Ed. 1996 May;63(5):321-30
8789877
N Engl J Med. 1975 Feb 13;292(7):344-7
1090839
Am J Med. 1983 Sep;75(3):433-8
6614029
Clin Neuropharmacol. 1992 Oct;15(5):327-51
1423335
J Assoc Physicians India. 1999 May;47(5):480-2
10778554
Med Clin (Barc). 1999 Apr 24;112(14):521-6
10363237
Rheumatology (Oxford). 2002 Jan;41(1):7-13
11792873
N Engl J Med. 1991 Nov 21;325(21):1487-98
1658649
Clin Exp Rheumatol. 1996 May-Jun;14(3):263-74
8809440
J Rheumatol. 1990 Oct;17(10):1329-34
2254890
N Engl J Med. 1975 Feb 20;292(8):403-7
1089199